Compare Nvidia Corp (NVDA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Recursion Pharmaceuticals Inc — how do they compare? Nvidia Corp trades at $221.22 (market cap $5.27T), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.78B). The key difference: Nvidia Corp is far larger — about 2960.7× Recursion Pharmaceuticals Inc's market cap, and Nvidia Corp pays a 0.46% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NVDA | RXRX | |
|---|---|---|
Market Cap | $5.27T | $1.78B |
Sector | Technology | Health |
52-Week High | $235.75 | $6.79 |
52-Week Low | $165.17 | $2.84 |
Enterprise Value | $5.20T | $1.30B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $223.96, up 2.27% on the day, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $1.87 surpassing the $1.76 expectation. Revenue surged to $130.50 billion in 2025, driving a net income margin of 62.97%. Analyst consensus is strongly bullish with a $325.86 price target, though RSI levels indicate potential overbought conditions near-term.
Outlook remains positive due to AI chip dominance and accelerating revenue growth, but risks include heightened valuations, competition, and market volatility. The stock offers significant upside to analyst targets, supported by robust cash flow and institutional backing, though investors should monitor execution against high expectations.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
